I hereby certify that this correspondence is being 13 2006 deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

DISCLOSURE STATEMENT
Examining Group 1632
Patent Application
Docket No. USF-182XC1
Serial No. 10/655,873

SUPPLEMENTAL INFORMATION

on November 6 2006

Glenn P. Ladwig, Patent Attorney

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Louis D. Lieto, Ph.D.

Art Unit

1632

Applicants

Shyam S. Mohapatra, Mukesh Kumar

Serial No.

10/655,873

Filed

September 5, 2003

For

Genetic Adjuvants for Immunotherapy

MS AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

11/13/2006 CNEGA1 00000004 190065 10655873

03 FC:1806

180.00 DA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

Docket No.: USF-182XC1

Serial No.: 10/655,873

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.: Address: 352-372-5800

P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Under the Paperwork control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Complete if Known			
Application Number	10/655,873		
Filing Date	September 5, 2003	3	
First Named Inventor	Shyam S. Mohapatra		
Group Art Unit	1632		
Examiner Name	Louis D. Lieto, Ph.D.		
Attorney Docket Number	USF-182XC1		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	R1	GILL, D.R. et al. "The development of gene therapy for diseases of the lung" Cell. Mol. Life Sci., 2004, 61:355-368.			
	R2	PERRICONE, M.A. et al. "Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium" <i>Human Gene Therapy</i> , 2001, 12:1383-1394.			
	R3	"Gene" from The American Heritage Dictionary of the English Language, 4 <sup>th</sup> Ed. (online), 2000 (retrieved on 2006-06-15). Retrieved from the Internet: <url: browse="" dictionary.reference.com="" gene="" http:="">.</url:>			
	R4	"Timolol Maleate" from RxList The Internet Drug Index (online), 2006 (retrieved on 2006-06-15). Retrieved from the Internet: <url: cgi="" generic3="" http:="" timololgfs_wcp.htm="" www.rxlist.com="">.</url:>			
	R5	"Respiratory tract" from Wikipedia (online), 2006 (retrieved on 2006-06-15). Retrieved from the Internet: <url: en.wikipedia.org="" http:="" respiratory_tract="" wiki="">.</url:>			
	R		<u> </u>		
	R				
	R				
	R				
	R				
	R				
	R				
	R				

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.